Compare MLTX & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLTX | CDNA |
|---|---|---|
| Founded | 2021 | 1998 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2020 | 2007 |
| Metric | MLTX | CDNA |
|---|---|---|
| Price | $17.84 | $17.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | $25.70 | ★ $27.33 |
| AVG Volume (30 Days) | ★ 1.1M | 556.0K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | N/A | $15.37 |
| Revenue Next Year | N/A | $11.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $5.95 | $10.96 |
| 52 Week High | $62.75 | $21.49 |
| Indicator | MLTX | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 56.37 | 35.33 |
| Support Level | $17.00 | $16.74 |
| Resistance Level | $19.15 | $20.94 |
| Average True Range (ATR) | 0.88 | 0.86 |
| MACD | -0.05 | -0.20 |
| Stochastic Oscillator | 37.35 | 18.01 |
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.